Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)

NCT05552755 is registered in ClinicalTrials.gov with Recursion Pharmaceuticals Inc. as lead sponsor.

NCT NCT05552755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)
Lead sponsor
Recursion Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2023
Completion date
September 30, 2027
Enrollment
67 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

familial adenomatous polyposis